Proliferative Lupus Nephritis Insights for Patients

Proliferative lupus nephritis is kidney inflammation caused by lupus in which the damage seen under a microscope involves the small blood vessels inside the kidney’s filters, a pattern that a kidney specialist calls class III or class IV and that needs prompt treatment to protect kidney function [4,8].

This page provides general information. It does not replace advice from a doctor or another qualified healthcare professional.

Key facts

Lupus nephritis is kidney inflammation caused by lupus. Proliferative lupus nephritis is the group of patterns known as class III and class IV, and it is the most common group seen on kidney samples [1,8].
A kidney biopsy, meaning a very small sample of kidney examined under a microscope, is the only way to establish the class, and the class guides the treatment [1,4].
Kidney involvement is often silent at first, so people with lupus have urine and blood tests regularly even when they feel well [2,4].
In a large international group of people followed from the time of their lupus diagnosis, 38.3 percent developed lupus nephritis, most of them at the very start [10].
The main aim of treatment is a complete renal response, meaning protein in the urine falls below a set level while kidney function holds steady [4].
There is no cure, though treatment has broadened considerably, with three targeted medicines now licensed for lupus nephritis in the United States [19,20,23].

What is proliferative lupus nephritis?

Lupus, or systemic lupus erythematosus, is a long-term autoimmune condition: the immune system attacks the body’s own healthy tissue. Our guide to systemic lupus erythematosus covers the whole condition. This page covers what happens when it inflames the kidneys.

Each kidney holds about a million tiny filters, each built around a knot of very small blood vessels called a glomerulus [3]. In lupus, clumps of antibodies settle in those filters and set off inflammation. That is lupus nephritis [1,3].

Lupus nephritis is not one thing. A kidney pathologist sorts what a kidney sample shows into six classes, using a system from the International Society of Nephrology and the Renal Pathology Society [4,7]. Two classes are called proliferative:

Class III, focal lupus nephritis: inflammation inside the filters’ blood vessels affects fewer than half the glomeruli in the sample [8].
Class IV, diffuse lupus nephritis: the same inflammation affects half or more [8].

Class V, membranous lupus nephritis, is different. The immune deposits sit along the outside of the filter wall, protein loss is usually heavy, and treatment follows a separate path [4,8]. Class V can occur alone or alongside class III or class IV [8].

You may also see the terms focal or diffuse lupus nephritis, and lupus glomerulonephritis. Other conditions inflame the same filters with no link to lupus, such as IgA nephropathy.

How common is it?

Prevalence means how many people have a condition now; incidence means how many are newly affected over a period.

Estimates vary with the population studied and how it was counted. Among 1,827 people followed for a mean of 4.6 years from their lupus diagnosis, 38.3 percent developed lupus nephritis [10]. The United States National Institute of Diabetes and Digestive and Kidney Diseases puts kidney disease at as many as 5 in 10 adults with lupus and 8 in 10 children [1]. Guidelines quote a lifetime range of 20 to 60 percent [4].

Where lupus nephritis is confirmed by biopsy, the proliferative classes are the largest group: roughly 50 percent class IV, 25 percent class III and 20 percent class V [8].

No reliable global count exists. Every figure counts diagnosed people, and most rest on biopsy records, so they reflect how readily biopsies are done.

Kidney involvement is more likely in people of African, Asian, Caribbean or Hispanic descent, in younger people, in men with lupus rather than women, and where lupus began in childhood [1,4,10]. Lupus itself is far more common in women, so most people with lupus nephritis are women [3].

What causes it?

Proliferative lupus nephritis is caused by lupus, and nobody knows what causes lupus. Research points to genes, hormones and triggers in the environment acting together [3]. Many gene variants, meaning small differences in the instructions inside cells, are linked to lupus, but lupus is not passed down in a simple pattern and no genetic test can diagnose it or predict kidney involvement [26].

The immune system makes antibodies against the body’s own material, and these stick together into clumps called immune complexes. Where the clumps lodge in the filters they draw in inflammatory cells and switch on part of the immune system called complement [3,27]. Low complement in the blood is one signal that the kidneys may be involved [26].

Nothing a person did caused it, there is no known way to prevent it, and it cannot be passed to anyone else [3].

What are the symptoms?

Early on there may be nothing to feel. Kidney involvement can stay silent for a long time, which is why regular urine and blood tests count for more here than symptoms do [2,4].

Symptoms, where they appear, can include [1,2,3]:

frothy or foamy urine, from protein leaking through damaged filters
swelling, called edema, in the ankles, feet, hands, face or abdomen
weight gain from retained fluid, sometimes weight loss
brown, pink or red urine, though blood is often present without being visible
unusual tiredness, and high blood pressure, which usually causes no symptoms

When to seek urgent help. Contact the kidney or lupus team without delay if swelling worsens over a few days, if the amount of urine passed drops suddenly, or if breathing becomes difficult, and urgently about a fever while taking medicines that damp down the immune system, since infection is a known risk of treatment [4]. Get emergency care for chest pain, severe breathlessness, a seizure, sudden confusion or sudden weakness [2].

How is it diagnosed?

Care is usually shared between a rheumatologist, who specializes in immune and joint conditions, and a nephrologist, a kidney specialist [3].

Since the kidneys can be affected silently, everyone with lupus is monitored: a blood creatinine level with an estimated filtering rate, urine tests including a protein-to-creatinine ratio, and blood tests for anti-double-stranded DNA antibodies and complement [4].

A kidney biopsy comes next. Guidelines suggest considering one when protein loss reaches about 500 mg a day, while warning that protein loss can look modest even in severe active nephritis [4]. The biopsy takes a tiny piece of kidney with a needle, under local anesthetic [1].

The biopsy establishes the class, and treatment cannot be chosen properly without it. Blood and urine results do not reliably show how much inflammation or scarring is present, and the pattern of damage decides which treatment fits [1,4].

The report carries two further scores [4,7,9]: an activity index for inflammation that may improve with treatment, and a chronicity index for scarring, which immune-calming medicines cannot reverse. A repeat biopsy is sometimes done later, where it is unclear whether a problem is fresh inflammation or old scarring [4].

How is it treated?

There is no cure. Treatment calms the inflammation, protects the filters that remain, and uses as little steroid as possible.

The target. Success is a complete renal response: protein in the urine below about 0.5 g per g of creatinine, with kidney function stable or improved, usually within 6 to 12 months [4,16].

For everyone. Hydroxychloroquine is recommended for everyone with lupus unless there is a reason not to use it, with eye monitoring during long-term use [4]. Blood pressure control, less salt, and an ACE inhibitor or an angiotensin receptor blocker are standard, since these also cut protein loss [1,4]. Guidelines list an SGLT2 inhibitor among kidney-protecting options for people who are stable, though its place here is unsettled, since people with lupus nephritis were left out of the trials that established these medicines [4,24].

Initial treatment of active class III or IV. Guidelines recommend glucocorticoids plus any one of: mycophenolate; low-dose cyclophosphamide into a vein; belimumab with either of those; or mycophenolate with a calcineurin inhibitor such as voclosporin or tacrolimus [4,15]. Steroids begin as a short course into a vein, then tablets reduced steadily [4].

Treatment continues rather than stopping. The 2024 American College of Rheumatology guideline treats lupus nephritis as continuous care, with immune-calming medicines carried on for three to five years in people reaching a complete renal response [6]. Mycophenolate is preferred for the longer phase, and azathioprine where a pregnancy is planned [4].

Newer targeted medicines. Three are licensed in the United States, each tested as an addition to standard treatment. Belimumab raised the main kidney response at two years from 32 to 43 percent [13,19]. Voclosporin raised complete renal response at one year from 23 to 41 percent [12,17]. Obinutuzumab raised it at 76 weeks from 33.1 to 46.4 percent, and was approved in October 2025 [14,20,23]. Belimumab and voclosporin are also authorized in the European Union [17,18]. Rituximab may be added where disease stays active, and availability differs greatly between countries [4,22].

Relapse and kidney failure. Relapse is common, reported in 10 to 50 percent of people, and is usually treated with the regimen that worked before [4]. Where the kidneys do fail, transplantation is preferred to long-term dialysis, and the condition returning in the new kidney is uncommon [4].

Living with proliferative lupus nephritis

Expect long-term follow-up with regular blood pressure checks, urine protein measurements and blood tests, shared between kidney and lupus teams [3,4]. Less salt, not smoking, a healthy weight and treating cholesterol protect both kidneys and heart. Treatment carries its own risks, so guidelines also list routine protections: infection screening and vaccination, antibiotics to prevent a specific chest infection, bone protection, and daily sunscreen, since ultraviolet light can set off lupus flares [4].

Family planning deserves its own conversation, early. Guidance is to avoid pregnancy while the nephritis is active, while taking medicines that can harm a developing baby, and for at least six months after the nephritis settles [4]. Mycophenolate carries a boxed warning about pregnancy loss and birth defects, so effective contraception is essential while taking it [21]. Cyclophosphamide can reduce fertility, so lifetime exposure is kept low and options such as freezing eggs or sperm are discussed beforehand [4]. Hydroxychloroquine is continued through pregnancy, and steroids, azathioprine and tacrolimus are considered acceptable [4,25].

It also helps to keep a record of swelling, weight and blood pressure, and to know who to contact out of hours.

Thinking about a clinical trial?

Clinical trials test whether a treatment works and is safe. Lupus nephritis is an active research area, so studies come up reasonably often. Deciding whether to look into one is personal, and it helps to take it in steps.

1. Understand what the study is asking

It is worth being clear on:

what the researchers want to learn, and what is being studied against what
how long it lasts, since lupus nephritis studies commonly run one to two years
which visits and tests are involved and how often, including urine collections and possibly a repeat kidney biopsy
the possible benefits, and the known and unknown risks
what happens when the study ends, including whether the treatment continues

2. Consider possible medical suitability

Every trial has rules about who can take part, called eligibility criteria. Some describe who can join, others who cannot. For a proliferative lupus nephritis study they might include a recent kidney biopsy showing active class III or class IV disease, protein in the urine above a set level, a kidney filtering rate above a floor, background mycophenolate at a steady dose, a steroid dose within limits, and reliable contraception. Studies often exclude people already on dialysis, people with very reduced kidney function, and people who have recently had another targeted medicine.

trialport’s medifit helps people consider information related to possible medical suitability. It does not diagnose a condition, confirm eligibility or replace formal screening by the study team.

Explore proliferative lupus nephritis clinical trials through trialport

3. Consider whether participation fits your life

Medical suitability is only part of the picture. A study can look right on paper and still be hard in practice. Worth thinking through:

the number of visits over a study lasting a year or more, and how long each takes
travel, distance, cost and who could come with you
work, school or caring responsibilities, and realistic time off
tiredness and flares, which can make a fixed visit schedule genuinely difficult
how you feel about drips, injections, repeated blood tests, urine collections or another biopsy
whether you understand the study well enough to decide, and whether it feels right now

trialport’s readifit helps people reflect on their understanding, motivation, time, routines, support, emotions and practical arrangements.

4. Ask questions before deciding

Useful questions for a research team:

Why is this study being done, and what is already known about the treatment?
What exactly would I need to do, and for how long?
What are the known risks, and what is still unknown?
Could I receive a placebo? A placebo is a dummy treatment with no active medicine, used so researchers can compare results fairly. Would I keep my usual treatment alongside it?
Would I have to change or stop mycophenolate, my steroid dose or hydroxychloroquine?
Would I need a repeat kidney biopsy, and if so, when?
What happens if my nephritis flares during the study?
Can I leave the study after joining, and what happens then?
Who looks after my usual kidney and lupus care, and who do I contact out of hours?

Taking part is voluntary. A person can ask questions, speak with people they trust and choose not to participate.

Search for clinical trials at app.trialport.com.

Current research

Study status checked: 3 August 2026. Research moves and what is studied changes, so this list will date. For current information, search at app.trialport.com.

Combining medicines from the start. The clearest shift of recent years is standard treatment plus one targeted medicine, with steroids reduced quickly. How best to combine them, and for how long, remains open [4,6,27].
B cells and their survival signals. Work continues on medicines that remove B cells or block the signals keeping them alive. Anifrolumab did not meet its main goal in a phase 2 study here [27].
CAR T cell therapy. A person’s own T cells are changed in a laboratory so they remove the immune cells making harmful antibodies. Early reports in severe lupus are encouraging, and no such treatment is approved for lupus nephritis [27].
Better tests and safe withdrawal. Open questions include whether blood or urine markers could replace some repeat biopsies, and when treatment can safely stop [4,26].

Support and further information

In the United States, the National Institute of Diabetes and Digestive and Kidney Diseases has a plain-language overview of lupus and the kidneys [1], and the National Kidney Foundation sets out treatment class by class, with video material in English and Spanish [2].

In the United Kingdom, Kidney Care UK covers lupus nephritis with commentary from a consultant nephrologist and accounts from people living with it [3], and Lupus UK is the national lupus charity [28].

Across Europe, Lupus Europe is the umbrella association of 32 national lupus organizations and can point people to a group in their own country and language [29].

Coverage elsewhere is thin. Where no local group exists, a national kidney association or the treating kidney unit is the best starting point.

Well-known people

Nick Cannon, the presenter, actor and musician, spoke about his diagnosis on American television in March 2012, saying “it’s a rare form of lupus that’s attacking my kidneys” and adding that “the technical term is lupus nephritis” [30]. Which biopsy class he has is not public.

Kidney failure has many causes and assumptions about someone’s diagnosis are often wrong, so this page names only people who have described this condition themselves.

Questions people often ask

Is proliferative lupus nephritis the same as lupus?
No. Lupus is the whole condition and can affect almost any part of the body. Lupus nephritis is what happens when it inflames the kidneys, and proliferative means the classes called III and IV [1,8]. Our guide to systemic lupus erythematosus covers the wider condition.

Do I really need a kidney biopsy?
Yes. It is the only way to establish the class, and blood and urine tests cannot show how much inflammation or scarring there is [1,4].

What is the difference between class III and class IV?
The kind of damage is the same. Class III means fewer than half of the filters in the sample are involved, class IV means half or more [8]. Class V, membranous, is a different pattern, treated differently [4,8].

Will my kidneys fail?
Not necessarily. In one international group, the estimated 10-year risk of kidney failure among people with lupus nephritis was 10.1 percent, and risk is higher with class IV [10,11]. Reaching and holding a complete renal response is what changes that path [4,16].

Can I have a baby?
Many people do. Guidance is to wait until the nephritis has been inactive for at least six months, and to change medicines that can harm a developing baby well in advance, so start that conversation early [4,25].

Does treatment ever stop?
Sometimes, though not quickly. Guidelines put the total length of immune-calming treatment at three years or more, with steroids reduced to the lowest possible dose [4,6].

Sources

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Lupus & Kidney Disease (Lupus Nephritis). https://www.niddk.nih.gov/health-information/kidney-disease/lupus-nephritis Accessed 3 August 2026.
National Kidney Foundation. Lupus nephritis. Last updated 10 May 2024, reviewed by the NKF Patient Education Team. https://www.kidney.org/kidney-topics/lupus-and-kidney-disease-lupus-nephritis Accessed 3 August 2026.
Kidney Care UK. Lupus nephritis. https://kidneycareuk.org/kidney-disease-information/kidney-conditions/lupus-nephritis/ Accessed 3 August 2026.
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney International. 2024;105(1S):S1-S69. https://kdigo.org/wp-content/uploads/2024/01/KDIGO-2024-Lupus-Nephritis-Guideline.pdf Accessed 3 August 2026.
Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney International. 2024;105(1):31-34. doi:10.1016/j.kint.2023.09.001. https://europepmc.org/article/MED/38182299 Accessed 3 August 2026.
Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis & Rheumatology. 2025;77(9):1115-1135. doi:10.1002/art.43212. https://europepmc.org/article/MED/40331662 Accessed 3 August 2026.
Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney International. 2018;93(4):789-796. doi:10.1016/j.kint.2017.11.023. https://europepmc.org/article/MED/29459092 Accessed 3 August 2026.
Uzzo M, Calatroni M, Moroni G. Not So Benign: Revisiting Pure Membranous Lupus Nephritis. Journal of Personalized Medicine. 2025;15(12):580. doi:10.3390/jpm15120580. https://pmc.ncbi.nlm.nih.gov/articles/PMC12734209/ Accessed 3 August 2026.
Choi SE, Fogo AB, Lim BJ. Histologic evaluation of activity and chronicity of lupus nephritis and its clinical significance. Kidney Research and Clinical Practice. 2023;42(2):166-173. doi:10.23876/j.krcp.22.083. https://pmc.ncbi.nlm.nih.gov/articles/PMC10085727/ Accessed 3 August 2026.
Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55(2):252-262. doi:10.1093/rheumatology/kev311. https://europepmc.org/article/MED/26342222 Accessed 3 August 2026.
Tektonidou MG, Dasgupta A, Ward MM. Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971-2015: A Systematic Review and Bayesian Meta-Analysis. Arthritis & Rheumatology. 2016;68(6):1432-1441. doi:10.1002/art.39594. https://europepmc.org/article/MED/26815601 Accessed 3 August 2026.
Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2021;397(10289):2070-2080. doi:10.1016/S0140-6736(21)00578-X. Abstract read in full as reproduced in the ACR Open Rheumatology Journal Club article at https://europepmc.org/article/MED/34463434 Accessed 3 August 2026.
Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. New England Journal of Medicine. 2020;383(12):1117-1128. doi:10.1056/NEJMoa2001180. https://europepmc.org/article/MED/32937045 Accessed 3 August 2026.
Furie R, Rovin BH, Garg JP, et al. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. New England Journal of Medicine. 2025;392(15):1471-1483. doi:10.1056/NEJMoa2410965. https://europepmc.org/article/MED/39927615 Accessed 3 August 2026.
Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Annals of the Rheumatic Diseases. 2010;69(1):61-64. doi:10.1136/ard.2008.102533. https://europepmc.org/article/MED/19155235 Accessed 3 August 2026.
Tamirou F, Lauwerys BR, Dall’Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Science & Medicine. 2015;2(1):e000123. doi:10.1136/lupus-2015-000123. https://europepmc.org/article/MED/26629352 Accessed 3 August 2026.
European Medicines Agency. Lupkynis (voclosporin): medicine overview. https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis Accessed 3 August 2026.
European Medicines Agency. Benlysta (belimumab): medicine overview. https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta Accessed 3 August 2026.
US Food and Drug Administration. BENLYSTA (belimumab) prescribing information, label effective 20 June 2025, retrieved from the openFDA drug label database. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22BENLYSTA%22 Accessed 3 August 2026.
US Food and Drug Administration. GAZYVA (obinutuzumab) prescribing information, label effective 19 December 2025, retrieved from the openFDA drug label database. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22GAZYVA%22 Accessed 3 August 2026.
US Food and Drug Administration. CELLCEPT (mycophenolate mofetil) prescribing information, label effective 25 November 2025, retrieved from the openFDA drug label database. https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22CELLCEPT%22 Accessed 3 August 2026.
National Institute for Health and Care Excellence (NICE). Obinutuzumab with mycophenolate mofetil for treating lupus nephritis. Technology appraisal guidance TA1131. Published 12 February 2026. https://www.nice.org.uk/guidance/ta1131 Accessed 3 August 2026.
Roche. FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis. Investor update, 20 October 2025. https://www.roche.com/investors/updates/inv-update-2025-10-20 Accessed 3 August 2026.
Vajgel G, Säemann MD, Kronbichler A. Sodium-Glucose Cotransporter 2 Inhibitors in Lupus Nephritis and ANCA-Associated Vasculitis: Unmet Needs to be Addressed. Glomerular Diseases. 2026;6(1):139-156. doi:10.1159/000551255. https://pmc.ncbi.nlm.nih.gov/articles/PMC13193701/ Accessed 3 August 2026.
Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology. 2020;72(4):529-556. doi:10.1002/art.41191. https://europepmc.org/article/MED/32090480 Accessed 3 August 2026.
Marchi-Silva R, De Aquino BM, Londe AC, et al. New Insights on Childhood Lupus Nephritis. International Journal of Nephrology and Renovascular Disease. 2025;18:1-12. doi:10.2147/IJNRD.S405789. https://pmc.ncbi.nlm.nih.gov/articles/PMC11740589/ Accessed 3 August 2026.
Zhu W, He H, Huang X, Zhang L, Pai P. The Evolution of Lupus Nephritis Therapy from the 1960s to the Present. Bioengineering. 2026;13(4):428. doi:10.3390/bioengineering13040428. https://pmc.ncbi.nlm.nih.gov/articles/PMC13113187/ Accessed 3 August 2026.
Lupus UK. What is lupus? https://www.lupusuk.org.uk/what-is-lupus/ Accessed 3 August 2026.
Lupus Europe. Mission, vision and core values. https://www.lupus-europe.org/about-lupus-europe/mission-vision-core-values/ Accessed 3 August 2026.
Bhattacharjee A. Nick Cannon has rare form of lupus. The Boston Globe. 6 March 2012. https://www.bostonglobe.com/lifestyle/health-wellness/2012/03/06/nick-cannon-has-rare-form-lupus/DlzOom7J5iGMA7uKMYWFBI/story.html Accessed 3 August 2026.

Review information

Written by: trialport editorial team
Reviewed by: Keith Berelowitz, Founder and CEO, trialport
Reviewed on: 3 August 2026
Next review due: 3 August 2027
References last checked: 3 August 2026

Proliferative lupus nephritis: a plain-language guide